Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Go back to Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 79.71 -0.2 (0.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.91 | 52 Week High | $10.00 | |||
| Open | $80.70 | 52 Week Low | $3.22 | |||
| Day High | $82.00 | P/E | N/A | |||
| Day Low | $77.38 | EPS | $-0.46 | |||
| Volume | 882,768 | |||||
